When PROTAC C was evaluated in cell lines with mutations in the p53 gene (Daudi cells: hematological cancer cells; colon cancer cells: HT-29; p53-/- HCT116), it showed a decrease in its ability to reduce cell viability, which was going to be in the order of 20–30% [67]. This evidence concerns the gene TP53 and hematopoietic and lymphoid cell neoplasm.